News

Wednesday, Apr 13 2022

ESSEX JUNCTION, VT; March 3, 2022 – Haematologic Technologies (“HT”), a global analytical and bioanalytical leader for large molecule drug development, today announced they’ll be operating under the new name, Prolytix — integrating HT and Haemtech Biopharma Services. This integration is bringing biotherapeutic, analytical CMC, and bioanalytical CRO services, expertise, and facilities together to support …

Haematologic Technologies Is Now Prolytix, Integrating to Support Growing Large Molecule Market Read More »

Thursday, Dec 16 2021

John Strokis to Lead the Quality Initiatives for the Company Through Next Phase of Growth ESSEX JUNCTION, Vt., Dec. 16, 2021 /PRNewswire/ — Haematologic Technologies (“HT”), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of John Strokis as Vice President, Quality. John will lead quality initiatives through the next phase of the Company’s growth, …

Haematologic Technologies Announces John Strokis as Vice President, Quality Read More »

Monday, Mar 1 2021

David Sunseri, Ph.D. to Lead the Company Through Next Phase of Growth March 1, 2021 – Essex Junction, VT:  Haematologic Technologies (“HTI”), a global leader in large molecule bioanalysis and biologic reagents, today announced the appointment of David Sunseri, Ph.D. as President and Chief Executive Officer. David will lead the next phase of the Company’s growth, …

Haematologic Technologies Announces David Sunseri, Ph.D., as President and Chief Executive Officer Read More »

Thursday, Oct 1 2020

Expanded Capabilities add to HTI’s Growing Large Molecule Bioanalysis Services Business September 30th, 2020 Essex Junction, VT –Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today announced the addition of a High Resolution Mass Spectrometry (HRMS) lab headed by Kevin …

Haematologic Technologies Adds a High Resolution Mass Spectrometry Lab Read More »

Thursday, Aug 20 2020

Greiner Bio-One and Haematologic Technologies Announce a Collaboration to Provide Complete Development and Manufacturing of Customized Blood Collection Tubes in Support of New IVDs, Clinical Diagnostics, and Large Volume Production MONROE, N.C. and ESSEX JCT., Vt., Aug. 20, 2020 /PRNewswire/ — Greiner Bio-One and Haematologic Technologies (HTI) are pleased to announce a collaboration to provide …

Haematologic Technologies Announces Collaboration with Greiner Bio-One Read More »

Tuesday, Mar 17 2020

Dear Customer: As an entrusted partner and service provider to you and your company, we would like to assure you that HTI is taking precautions not only to maintain business continuity, but also to ensure the safety and well being of our staff and our clients. To ensure that we are able to provide uninterrupted …

Statement concerning COVID-19 Read More »

Friday, Oct 11 2019

Joint News Release HTI Media Contact:Robert Myers, VP of Business DevelopmentTel.: (802) 878-1777Email: rmyers@haemtech.net Edgewater Media Contact:Robert Girton, PartnerTel.: (216) 292-3858Email: rgirton@edgewatercapital.com Edgewater Capital Partners to Acquire Haematologic Technologies Essex Junction, VT and Cleveland, OH, October 11, 2019 – Edgewater Capital Partners announced today that they have entered into an agreement to acquire Haematologic Technologies Incorporated, a …

Edgewater Capital Partners to Acquire Haematologic Technologies Read More »

Tuesday, Aug 28 2018

When evaluating drug candidates that treat hemostasis directly, or those that have potential off-target coagulation effects, understanding their impact on blood coagulation is essential. Several assays can measure a drug candidate’s impact on hemostasis by evaluating patient plasma samples throughout the clinical trial process. Using this information, drug manufacturers can increase the safety of their …

Does your drug create a clotting problem? Read More »